MACK News and Press, Merrimack Pharmaceuticals Inc. From 03/06/19

Merrimack Pharmaceuticals (NASDAQ: MACK ): FY GAAP EPS of -$4.55. More news on: Merrimack Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more ...

CAMBRIDGE, Mass. , March 6, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced its fourth quarter and full year 2018 financial results for the period ended December 31, 2018 . ...

On February 6, 2019, MacroGenics ( MGNX ) reported that the SOPHIA trial comparing margetuximab plus chemotherapy to Herceptin plus chemotherapy met the primary endpoint of progression free survival with a hazard ratio of 0.76 with an accompanying p-value of 0.033. This rather surprising res...

NEW YORK, Feb. 12, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ON Semiconductor Corporation (NASDAQ:ON), Entegris, Inc. (NASDAQ:ENTG), U...